Exchange & Returns Information
Review Details
(3)
| Drug Type | Original |
|---|---|
| Active Ingredient | ENCORAFENIB |
| Strength | 75MG |
| Manufacturer | INTAS PHARMACEUTICALS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 180 CAPSULES | $ 0.36 | $ 64.00 |
$ 54.40
Apply ZARVY26 (-15%)
You save $ 9.60
|
||
| 2 BOXES - 360 CAPSULES | $ 0.37 | $ 134.00 |
$ 113.90
Apply ZARVY26 (-15%)
You save $ 20.10
|
||
| ★ Best Value 3 BOXES - 540 CAPSULES | $ 0.37 | $ 202.00 |
$ 171.70
Apply ZARVY26 (-15%)
You save $ 30.30
|
Reference information will be available soon.
Braftovi 75mg is an oral BRAF inhibitor formulated with Encorafenib, a next-generation targeted therapy designed to block mutated BRAF V600E or V600K proteins in cancer cells. It is specifically used in combination regimens, not as monotherapy, to enhance effectiveness in treating BRAF-mutated cancers. Braftovi works by disrupting abnormal signaling in the MAPK/ERK pathway, which drives tumor growth in specific cancer types. It has been shown to improve progression-free survival in patients with melanoma, colorectal cancer, and lung cancer when combined with appropriate agents like Binimetinib or Cetuximab.
- AntiCancer Drugs > Non-Small Cell Lung Cancer (NSCLC) Used in combination with Binimetinib for the treatment of advanced or metastatic NSCLC with confirmed BRAF V600E mutation. Offers targeted suppression of tumor growth pathways and is reserved for patients who are ineligible for curative surgery. > Unresectable or Metastatic Melanoma Indicated with Binimetinib for patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. Helps delay disease progression and improve overall response when first-line therapies are no longer effective. > Metastatic Colorectal Cancer (mCRC) Used with Cetuximab in patients with metastatic colorectal cancer confirmed to have BRAF V600E mutation. Provides targeted intervention in combination therapy to reduce tumor progression when standard therapies fail.
- Selective BRAF inhibitor that targets the V600-mutant forms of the BRAF protein, reducing hyperactive MAPK pathway signaling in tumors - Improves clinical outcomes when used in combination therapy in BRAF-mutated cancers - Not effective as monotherapy; always combined with Binimetinib or Cetuximab depending on cancer type
Melanoma or NSCLC: - 450 mg orally once daily (usually 6 tablets) - Administered in combination with Binimetinib - Treatment continued until disease progression or unacceptable toxicity - If Binimetinib is stopped, reduce dose to 300 mg daily Colorectal Cancer (mCRC): - 300 mg orally once daily - Used in combination with Cetuximab - Treatment continued until progression or toxicity - Discontinue Encorafenib if Cetuximab is stopped General Comments: - Ensure BRAF V600E or V600K mutation confirmation via FDA-approved test before initiation - Swallow capsules whole, with or without food - Dose adjustments may be required based on tolerability and combination agent status
Store at room temperature (20°C to 25°C). Protect from moisture and heat. Keep the bottle tightly closed and out of reach of children.
Common adverse effects include fatigue, nausea, joint pain, and rash. Serious side effects may involve QT prolongation, liver enzyme elevation, hemorrhage, and photosensitivity. Monitor ECG and liver function regularly. Risk of new primary malignancies (e.g., cutaneous squamous cell carcinoma) also exists; perform dermatologic evaluations periodically.
Braftovi is a key part of my melanoma treatment. This pharmacy has been a 100% reliable source for it month after month.
การได้รับยา Braftovi ตรงเวลาเป็นสิ่งสำคัญมากสำหรับการรักษาของฉัน บริการของที่นี่น่าเชื่อถือและเป็นมืออาชีพเสมอ
我的治疗方案需要服用Braftovi。这家药房能稳定供货，而且服务专业、注重隐私，让我非常安心。
No combo deals available at the moment.
